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Abstract 
Background: There is an urgency to develop robust prognostic biomarkers for metastatic colorectal 
cancer (mCRC) patients receiving chemotherapy. The current study aimed to examine the prognostic 
significance of circulating tumour cells (CTCs) and to develop a prognostic model incorporating CTCs in 
predicting the outcomes of mCRC patients treated with chemotherapy.  
Methods: Our study prospectively enrolled 55 mCRC patients who had undergone palliative 
chemotherapy between 2011 and 2014. Baseline CTCs and clinicopathological variables predictive of 
survival outcome were identified using univariate analysis. Negative selection-based protocol plus flow 
cytometry was used for CTC identification.  
Results: The median overall survival (OS) and progression-free survival (PFS) were 24.2 months and 8.7 
months, respectively. CTCs were detected in all the patients, and the median number of CTCs was 
30.8/mL (range: 5.8–431.3/mL). The median OS and PFS were 37.1 and 13.3 months, respectively, for 
patients with CTC number ≤30/mL, while the median OS and PFS were 14.9 months and 5.1 months, 
respectively, for patients with CTC number >30/mL (both P<0.001). A prognostic model using CTCs in 
conjunction with other independent clinical variables further stratified patients into good and poor 
prognostic groups. The median OS and PFS were 32.4 and 11.5 months, respectively, in the good 
prognostic group and 5.4 and 2.7 months, respectively, in the poor prognostic group.  
Conclusions: We developed a reliable CTC-based prognostic model for the prediction of clinical 
outcomes in mCRC patients treated with chemotherapy. This model may be used to assist clinicians in 
identifying those with the poorest prognosis before treatment. 
Key words: metastatic colorectal cancer, circulating tumour cell, palliative chemotherapy, prognosis, model 
Introduction 
Colorectal cancer (CRC) is one of the most 
common and lethal cancers, accounting for 10% of 
new cancer cases and 8.5% of total cancer-related 
deaths worldwide in 2012.[1] Systemic chemotherapy 
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remains the most effective therapy for patients with 
unresected metastatic colorectal cancer (mCRC), and 
the median survival duration is now approaching 30 
months for patients treated with cytotoxic 
chemotherapy and biologic agents targeting 
angiogenesis and the epidermal growth factor 
receptor.[2, 3] Although the treatment response of 
these combinations has been fairly improved in the 
modern era, some patients who did not respond to 
these systemic treatments still have a dismal outcome. 
Indeed, approximately 28-44% of patients have no 
response to the first-line treatment with doublet 
chemotherapy plus either cetuximab or 
bevacizuamb.[2] Therefore, there is an urgency to 
develop robust prognostic biomarkers for mCRC 
patients receiving chemotherapy. Unfortunately, 
there has not yet been an accepted biologic or 
molecular marker of prognostic value for systemic 
chemotherapy.  
 In recent years, circulating tumour cells (CTCs) has 
been widely proposed to serve as biomarkers in 
various cancer types, including breast,[4, 5] 
prostate[6] and colorectal[7, 8] cancers. CTCs are cells 
migrating from solid tumours into the peripheral 
blood, which represent a disseminated disease and 
poor prognosis.[9-11] The CellSearch platform 
(Veridex, Raritan, NJ) is the only system approved by 
the US Food and Drug Administration to detect CTCs 
since 2004.[4] In 2008, Cohen et al first reported using 
the number of CTCs as a prognostic and predictive 
value for survival outcome and treatment response in 
mCRC patients treated with systemic chemotherapy. 
[7] However, the application of CTCs to predict the 
clinical outcomes of mCRC remains uncertain due to 
the relatively low efficiency of detection rate by the 
CellSearch platform[11] and no other device has been 
proven to be a standard method to date. In addition to 
CTCs, a number of clinical variables with predictive 
values have been identified in patients with mCRC 
receiving chemotherapy, including patient perform-
ance, [12] anatomic extent of the tumour,[13] 
histologic subtype,[14, 15] tumour grade,[16] serum 
tumour marker carcinoembryonic antigen (CEA),[17] 
and history of colectomy.[18] We hypothesized that a 
reliable prognostic tool combing clinicopathological 
features and CTCs for predicting the survival 
outcome and tumour response for mCRC patients 
would be most useful and possibly better to identify 
patients with the best and poorest prognoses rather 
than CTCs alone. To achieve this, the current study 
aimed to examine the prognostic significance of CTCs 
by using an easy-to-perform CTC detection platform 
using negative selection strategy and to develop a 
prognostic model that incorporates CTCs with other 
important clinical variables in predicting the survival 
outcome and tumour response in mCRC patients 
treated with systemic chemotherapy, especially to 
identify those patients with the poorest survival 
outcome to systemic chemotherapy.  
Methods 
Patient selection and treatment of systemic 
chemotherapy 
This study was designed as a prospective 
observational study at a single institute. In total, 
fifty-five patients who had a histological diagnosis of 
CRC and were receiving systemic chemotherapy 
treatment at Chang Gung Memorial Hospital 
(CGMH) Linkou branch between January 2011 and 
June 2014 were prospectively enrolled. The eligibility 
criteria included patients over 20 years of age, patients 
with unresected metastatic disease, and patients with 
a measurable lesion confirmed by image studies. 
Patients who received concurrent radiotherapy or 
palliative tumour resection within 28 days of 
palliative chemotherapy and those who received local 
ablation therapy during the enrolment period were 
excluded. All patients underwent a baseline 
evaluation that included demographic data, clinical 
history, pathological characteristics, computed 
tomography (CT) scan, and biochemical evaluation. 
Systemic antitumour therapy consisted of a doublet 
combination of cytotoxic chemotherapy with or 
without bevacizumab or cetuximab (limited in 
patients with KRAS wild type), depending on the 
physician’s decision. Tumour response was evaluated 
by CT scan according to the response evaluation 
criteria in solid tumours (RECIST) 1.1.[19] Image 
studies were performed and interpreted by an 
institutional radiologist at baseline and were repeated 
every 8–12 weeks (the exact interval was at the 
physician’s discretion) to evaluate tumour response. 
The overall survival (OS) and progression-free 
survival (PFS) lengths were calculated from the date 
of administration of the first cycle of palliative 
chemotherapy to the date of death or disease 
progression after chemotherapy. All patients were 
followed-up until death or June 30, 2016. The study 
protocol was approved by the Institutional Review 
Board of CGMH (IRB number 101-2161C and 
102-2407B). Written informed consent to participate 
was obtained from all the patients. 
Measurement of peripheral circulating tumour 
cells  
CTC analysis was performed using a protocol of 
combined negative selection and positive detection 
strategies, which was designed and validated in our 
previous reports.[20, 21] Briefly, the methods were (1) 
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a negative selection protocol for effective RBC and 
leukocyte depletion by red blood cell lysis and a CD45 
depletion kit and (2) flow cytometry to quantitatively 
identify CTCs and calculate their numbers. The CTC 
identification was validated with a recovery rate of 
44.6 ± 9.1% and a coefficient of variation of 20.4%.[20] 
For CTC tests, 4 mL of peripheral blood was 
used after discarding the first 4 mL of blood to avoid 
epithelial contamination. Red blood cell lysis was 
performed within 72 hours after blood drawing. 
Samples were then negatively enriched by adding 
EasySep CD45 Depletion Cocktail (STEMCELL 
Technologies Inc., Vancouver, BC, Canada) at 25 
μL/mL to the cells and EasySep Magnetic 
Nanoparticles (STEMCELL) at 50 μL/mL to the cells. 
Immunomagnetically enriched samples containing 
spiked HCT116 cells were collected and labelled with 
Alexa Fluor® 488-conjugated anti-EpCAM monoant-
ibody (1:400 dilution; Cell Signalling Technology, Inc., 
Danvers, MA, USA.) and a novel DNA-detecting 
far-red-fluorescing dye, Draq5 (50μM, Abcam, 
Cambridge, MA, USA), for nuclear staining. The 
isotype for EpCAM was also used for internal 
controls. In addition, we routinely used 4 mL of 
peripheral blood drawn from healthy individuals that 
was spiked with and without 1000 HCT116 cells (a 
colon cancer cell line, which was obtained from the 
Food Industry Research and Development Institute, 
Taiwan) for controls during the trial. The performance 
recovery, which was defined as the number of 
HCT116 cells detected by flow cytometry (BD 
FACSCalibur, BD Biosciences, San Jose, CA, USA) 
divided by the number of spiked HCT116 cells, and 
the coefficient of variation (CV) value have been 
calculated and reported to be stable in a previous 
report.[20] CTCs were defined as the cells that were 
positive both for EpCAM and Draq5. Serum CEA 
levels of enrolled patients were measured by standard 
kit purchased from Siemens ADVIA Centaur 
Chemiluminescent Immunoassay, Siemens Siemens 
Healthcare GmbH, Germany. 
Statistical analysis 
The patients’ demographic data were 
summarized as the number (%) for categorical 
variables, and the median, 95% confidence interval 
(CI), and range for continuous variables. Eleven 
predefined variables, included age, gender, primary 
tumor site, histological grade, American Joint 
Committee on Cancer (AJCC) staging group, Eastern 
Cooperative Oncology Group (ECOG) performance 
scale, KRAS mutation status, CEA level, CTC numbers, 
previous history of colectomy, and chemotherapy 
regimens, recorded within 7 days before the first cycle 
of palliative chemotherapy in mCRC patients, were 
then evaluated to ascertain their impact on OS and 
PFS. These potentially key prognostic variables were 
selected because minimal data were missing, and they 
could widely represent the available clinical data, 
which makes the findings broadly applicable. 
Variables with a P value < 0.10 in the univariate 
analysis were included for analysis in the multivariate 
model. Multivariate Cox’s proportional hazard model 
analysis was performed to investigate the impact of 
independent factors on OS and PFS. A risk model was 
developed from a multivariate logistic regression. The 
β-coefficients from the risk model were used to 
generate the points of the prognostic score for 
calculating survival time. Akaike’s information 
criterion (AIC) was used to develop different 
multivariate models by systematically removing 
predictors from a full model that contained all 
predictive factors that were found to be statistically 
significant in the multivariate analysis. Receiver 
operating characteristic (ROC) curves and the area 
under the curve (c-statistic) for the outcome of 
survival at 1, 2, and 3 years were calculated to 
determine the accuracy of the prognostic score. 
Patients were further stratified into two prognostic 
groups according to their total score obtained from 
the prognostic score. Fisher’s exact test was 
performed to determine significant associations 
between the tumour responses of the chemotherapy 
and prognostic groups. OS and PFS among different 
prognostic categories were calculated according to the 
Kaplan–Meier method. Log-rank tests were used to 
determine significant differences among the survival 
curves. SPSS 17.0 software (SPSS Inc., Chicago, IL) 
was used for all the statistical analyses. All statistical 
assessments were 2-sided. A P value of less than 0.05 
was considered significant. 
Results 
Table 1 shows the demographic data of the 55 
patients. The median age was 60 years (range: 36–88 
years), and 61.8% of the patients were male. Forty-two 
patients (76.4%) had a tumour that originated from 
the colon, and 13 patients (23.6%) had tumours that 
originated from the rectum. Moderately differentiated 
adenocarcinoma was the most common histological 
differentiation subtype (38 patients, 69.1%), followed 
by poorly (14 patients, 25.5%) and well-differentiated 
(3 patients, 5.5%) subtypes. Seventeen patients (30.9%) 
had a mutated KRAS gene, and 23 patients (41.8%) 
had previously undergone a colectomy for primary 
tumour resection. All the patients received 
5-fluouracial based doublet chemotherapy. CTCs 
were detected in all the patients. The median number 
of CTCs was 30.8/mL (range: 5.8–431.3/mL). There 
was no significant difference of CTC numbers among 
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patients with different tumor stage and T- or N- 
classification (Figure 1). Eighteen patients (32.7%) had 
a normal baseline carcinoembryonic antigen (CEA) 
level (≤5 ng/dL), and the median serum level of CEA 
was 10.5 ng/dL (range: 0.7 –2558 ng/dL) among all 
the patients. 
 
Table 1. Patients’ demographic data 
Variable Category  no % 
Age, year Median (range) 60 (36–88)   
Gender male 34 61.8 
  female 21 38.2 
Primary tumour site colon 42 76.4 
  rectum 13 23.6 
Histological grade well 3 5.5 
  moderately 38 69.1 
  poorly 14 25.5 
AJCC Stage, 7th edition 4a 21 34.5 
  4b 34 65.5 
ECOG performance scale 0 11 20.0 
  1 25 45.5 
  2~3 19 34.5 
KRAS mutation status no mutation 38 69.1 
  mutation 17 30.9 
CEA, ng/dL median (range) 10.5 (0.7–2558)   
  ≤5 18 32.6 
  >5 37 67.4 
CTC, number/mL median (range)  36.8 (5.8–431.3)   
Previous history of colectomy no 32 58.2 
  yes 23 41.8 
Line of chemotherapy 1 53 96.4 
  2 1 1.8 
  3 1 1.8 
Chemotherapy regimen Fluorouracil 55 100 
 Irinotecan 39 70.9 
 Oxaliplatin  16 29.1 
 Bevacizumab 34 61.8 
 Cetuximab 7 12.7 
AJCC: American Joint Committee on Cancer; ECOG: Eastern Cooperative 
Oncology Group  
CEA: carcinoembryonic antigen; CTC: circulating tumour cell 
 
 
At the study end, 42 patients (76.4%) died during 
the study. The median OS and PFS were 24.2 months 
(95% CI: 14.0–34.4 months) and 8.7 months (95% CI: 
6.1–11.3 months), respectively. The 1-, 2-, and 3-year 
survival rates were 74.5%, 50.2%, and 31.9%, 
respectively. The results of the univariate analyses for 
OS and PFS that were associated with the clinical 
variables are presented in Table 2. Based on the 
univariate analysis of the imputed data set, 6 of the 11 
preselected variables, including primary tumour side, 
tumour stage, histological grade, previous history of 
colectomy, ECOG performance scale, and CTCs, 
showed a statistically significant effect on OS. 
However, the multivariate analysis identified tumour 
stage, histological grade, previous history of 
colectomy, ECOG performance score, and number of 
CTCs as the only independent prognostic factors 
(Figure 2). Regarding the PFS of all the patients, 3 of 
the 11 preselected variables, including previous 
history of colectomy, ECOG performance scale and 
number of CTCs, were significant variables in both 
the univariate analysis and multivariate analysis. 
Using the median number of CTCs as the cut-off 
point, the median OS and PFS were 37.1 months (95% 
CI: 22.6–51.6 months) and 13.3 months (95% CI: 
11.7–14.9 months), respectively, for patients with CTC 
number ≤30/mL, while the median OS and PFS were 
14.9 months (95% CI: 8.6–21.2 months) and 5.1 months 
(95% CI: 3.5–6.7 months), respectively, for patients 
with CTC number >30/mL (both P<0.001, Figure 3). 
The risk model and scoring system of the 
prognostic score generated from β-coefficients of 
multivariate analysis for OS are shown in Table 3. The 
total prognostic scores ranged from 0 to 6. Using the 
prognostic score, patients were stratified into good 
(total score of 0–3) and poor (total score of 4–6) 
prognostic groups. This prognostic scoring system 
assigned 70.9% of the patients to the good prognostic 
group and 29.1% of the patients to the poor prognostic 
group. The median OS in the good and poor 
prognostic risk groups were 32.4 months (95% CI: 
23.0–41.8 months) and 5.4 months (95% CI: 2.1–8.7 
months), respectively (Figure 4A). The hazard ratio 
was 10.3 (95% CI: 3.4–23.5; P < 0.001) when comparing 
the poor and good prognostic groups. Accordingly, 
the median PFS in the good and poor prognostic risk 
groups was 11.5 months (range: 8.4–14.6 months) and 
2.7 months (range: 1.3–4.1 months), respectively, with 
a hazard ratio of 5.15 (95% CI: 2.68-9.57; P < 0.001) 
(Figure 4B). The c-statistic that was obtained using 
ROC curve analysis for mortality within 1, 2, and 3 
years was 0.82 (95% CI: 0.71–0.94), 0.83 (95% CI: 
0.72–0.93), and 0.72 (95% CI: 0.58–0.86), respectively. 
The AIC was 230.6 for the full model and 257.3 after 
removal of the variable of CTCs from the full model. 
A smaller AIC value indicated a higher capacity for 
predictive stratification in the prognostic model. 
Table 4 compared the performance of CTC numbers, 
clinical parameter scoring system except CTC and 
combined CTC numbers and clinical parameter 
scoring system (full score) for OS and PFS. The results 
showed the full score and CTC number performed 
well both for PFS and OS while clinical parameters 
did not. Therefore, our findings suggest CTC alone 
could have good performance for outcome prediction, 
but better performance was found when combined 
with clinical parameters. 
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Table 2. Univariate analyses for overall survival (OS) and progression-free survival (PFS)  
      Univariate for OS  Univariate for PFS 
Variable Category  No (%) No of event (%) median  95% CI p  No of 
event 
(%) 
median  95% CI p 
Overall   55 (100) 42 (76.4) 24.2 14.0–34.4    54 (98.2) 8.7 6.1–11.3   
Age ≤60 28 (50.9) 19 (67.9) 26.2 17.8–34.6 0.13  27 (96.4) 9.1 6.4-11.8 0.34 
  > 60 27 (49.1) 23 (85.2) 19.8 4.4–35.2    27 (100) 7.5 5.5–9.5   
Gender male 34 (61.8)) 25 (73.5) 25.1 16.9–33.3 0.6  33 (97.1) 8.7 5.7–11.7 0.46 
  female 21 (38.2) 17 (81.0) 19.8 8.6–30.9    21 (100) 7.5 4.7–10.3   
Primary site colon 42 (76.4) 29 (69.0) 26.2 19.8–32.6 0.047  41 (97.6) 8.2 5.6–10.8 0.49 
  rectum 13 (33.6) 13 (100) 15.7 10.1–21.3    13 (100) 9.7 2.3–17.1   
AJCC stage, 7th IVa 21 (38.2) 14 (66.7) 34.6 22.6–46.4 0.026  20 (95.2) 12.9 6.8–19.0 0.17 
 IVb 34 (61.8) 28 (82.4) 15.7 11.4–20.0    34 (100) 7.8 6.8–8.8   
Grade 
 
well or moderately 41 (74.5) 31 (75.6) 26.3 20.3–32.3 0.008   
40 (97.6) 
9.1 6.5–11.7 0.69 
poorly 14 (25.5) 11 (78.6) 12.5 4.2–20.8    14 (100) 7.5 6.6–8.4   
Previous history of 
colectomy 
yes 23 (41.8) 12 (52.2) 43.9 12.9–74.9 <0.001  22 (95.7) 12.8 7.9–17.7 0.022 
no 32 (58.2)  
30 (93.8) 
15.7 9.6–21.8     
32 (100) 
7.2 4.9–9.5   
KRAS mutation 
  
mutant  17 (30.9) 14 (82.4) 17.4 7.0–27.8 0.27  17 (100) 7.2 1.7–12.7 0.63 
no mutant 38 (69.1) 28 (73.7) 27.7 18.9–36.6    37 (97.4) 9.7 6.8–12.6   
Chemotherapy regimen Oxaliplatin-based 17 (30.9) 13 (76.5) 15.7 8.6–22.8 0.48  17 (100) 5.4 0.0–9.8 0.14 
Irinotecan-based 38 (69.1) 29 (76.3) 26.3 17.6–34.9    37 (97.4) 10.6 8.3–12.9   
ECOG performance 0~1 36 (65.5) 24 (66.7) 31.8 21.0–42.6 <0.001  35 (97.2) 11.5 8.0–15.0 <0.001 
2~4 19 (45.5) 18 (94.7) 10.8 1.7–19.9    19 (100) 3.8 2.1–5.5   
CEA level, ng/dL ≤5 18 (32.7) 13 (72.2) 25.1 14.0–36.2 0.92  17 (94.4) 7.4 2.0–12.8 0.57 
>5 37 (67.3) 29 (78.4) 21.6 9.2–34.0    37 (100) 10 6.7–13.3   
CTC, numbers/  
mL 
≤30 26 (47.3) 17 (65.4) 37.1 22.5–51.6 0.005  25 (96.2)) 13.3 11.7–14.9 <0.001 
>30 29 (52.7) 25 (86.2) 14.9 8.9–21.2    29 (100) 5.1 3.5–6.7   
AJCC: American Joint Committee on Cancer; ECOG: Eastern Cooperative Oncology Group 
CEA: carcinoembryonic antigen; CTC: circulating tumour cell  
 
 
Table 3. Point scoring of overall survival for the prognostic 
models 
Variable  
 
Point 
0 1 2 
AJCC 7th stage IVa IVb  
CTC number, per mL ≤30 >30  
ECOG performance 0–1  2-3 
Histological grade well or moderately poorly  
Previous history of colectomy  yes no  
AJCC: American Joint Committee on Cancer; CTC: circulating tumour cell; ECOG: 
Eastern Cooperative Oncology Group 
 
 
Overall, chemotherapy resulted in tumours 
showing a partial response in 26 (47.3%) patients, 
stable disease in 13 (23.6%) patients, and progressive 
disease in the remaining 16 (29.1%) patients. The 
treatment response to a partial response, stable 
disease, and progressive disease of tumours were 25 
(64.1%) patients, 11 (28.2%) patients, and 3 (7.7%) 
patients, respectively, in patients from the good risk 
group, while the treatment responses to a partial 
response, stable disease, and progressive disease of 
tumours were 1 (6.3%) patient, 2 (12.5%) patients, and 
16 (81.3%) patients, respectively, in the poor risk 
group (Fisher’s exact test P<0.001, Figure 5). Figure 6 
presents the correlations between Kras mutation 
status and CTC numbers (6a) as well as targeted 
agents and CTC numbers (6b). There was no 
significant difference of CTC numbers between 
patients with Kras mutant and wild type 
(Mann-Whitney U test p = 0.879) as well as CTC 
numbers between patients received bevacizumab- 
based for cetuximab-based chemotherapies (Mann- 
Whitney U test p = 0.933). 
 
Table 4. The performance of CTC numbers, clinical parameter 
scoring system except CTC and combined CTC numbers and 
clinical parameter scoring system (full score) for OS and PFS 
  Hazard Ratio (95% CI) p value 
For OS   
CTC alone (> 30 vs ≤ 30 cells/mL) 2.613(1.385-4.928) 0.003 
Clinical parameter scoring except CTC 3.266(1.715-6.219) <0.001 
Full Score 6.135(1.867-20.161) 0.003 
For PFS   
CTC alone (> 30 vs ≤ 30 cells/mL) 4.942(2.600-9.392) <0.001 
Clinical parameter scoring except CTC 1.830(1.041-3.217) 0.036 
Full Score 3.741(1.631-8.581) 0.002 
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Figure 1. Difference of CTC numbers among different tumor stage (1A), and T- or N- classification (Figure 1B) 
 
 
Figure 2. Multivariate analysis for overall survival and progression-free survival. 
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Figure 3. Kaplan-Meier overall survival (A) and progression-free survival (B) curves for patients, stratified according to the number of circulating tumour cells. 
 
  
Figure 4. Kaplan-Meier overall survival (A) and progression-free survival (B) curves for patients, stratified according to the prognostic model. 
 
 
Figure 5. Tumour response rate to chemotherapy, stratified according to the prognostic model. 
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Figure 6 presents the correlations between Kras mutation status and CTC numbers (6A) as well as targeted agents and CTC numbers (6B). 
 
Discussion 
mCRC is a common and lethal malignancy both 
in Taiwan and worldwide. 1, [22] Though the survival 
outcome and treatment response to chemotherapy 
plus a biologic agent had dramatic advances in the 
modern era, a small subset of patients still had a 
dismal outcome, which implies a stubbornness to 
antitumour treatment.[2, 3] Therefore, a prognostic 
model for picking up on those with the poorest 
outcomes in antitumour therapy may assist clinicians 
and patients in decision making. Our study 
developed a prognostic model that predicts survival 
outcome in patients with mCRCs, using CTCs in 
conjunction with other significant clinical variables. 
This model accurately predicted survival outcome 
with c-indices of 0.824, 0.828, and 0.719 for the 
probability of 1-, 2-, and 3-year mortalities. Our study 
showed that this model might be informative for 
clinicians and patients with mCRCs for estimating the 
survival outcome after systemic chemotherapy.  
Tumour stage13, histological grade[16], previous 
colectomy[18], and ECOG scale[12] are the 
well-established prognostic factors in patients with 
mCRC. Advanced stage and poor histological grade 
represented aggressive tumour behaviour. A 
population-based study including 37,793 mCRC 
patients recently reported that palliative primary 
tumour resection was associated with improved 
overall and cancer-specific survival.[18] A lower 
ECOG scale represented a better ability of daily 
activity and general health status[23, 24], which were 
associated with the eligibility to receive 
chemotherapy and a lower incidence of 
treatment-related toxicity. These are all possible 
reasons for explaining why the ECOG scale 
contributed the most in our model. Our study 
identified that the baseline number of CTCs prior to 
chemotherapy was an independent prognostic factor 
for overall survival and a predictive factor for PFS and 
tumour response in mCRC patients. Furthermore, 
conjunction of the CTCs with other prognostic clinical 
variables increased the discrimination power of the 
model (AIC value decreased from 257.3 to 230.6 after 
the CTC variable was added into the full model). Our 
result encourages integrating CTCs and clinical 
variables for predicting the outcome of mCRC 
patients receiving systemic chemotherapy. Patients 
with a good prognosis may be encouraged to receive 
palliative chemotherapy to gain the maximal benefit 
of the treatment. In contrast, palliative chemotherapy 
may be futile in patients with a poor prognosis, given 
that the median OS, PFS, and tumour response of 
these patients were only 5.4 months, 2.7 months and 
6.3%, respectively.  
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The number of CTCs is an emerging biomarker 
that has been shown to be an independent prognostic 
factor in numerous studies of various solid cancers 
and CRC.[4-7] In general, higher CTC counts have 
been consistently associated with disseminated stage 
and aggressive tumour biology.[10, 11, 25] Cohen et al 
first reported that patients with CTC number ≥3 per 
7.5 mL of peripheral blood had a shorter median 
survival based on a prospective multicentre study of 
430 mCRC patients.[7] In their report, the distribution 
of the number of CTCs per 7.5 mL of peripheral blood 
using the CellSearch system as undetectable, 1 to 2, 
and 3 or more were 48%, 26%, and 26%, respectively. 
Furthermore, two large-scale meta-analysis studies, 
which included 3094 patients in the first study and 
1329 patients in the second study, showed that the 
detection of CTCs correlated with a poor prognosis 
for CRC patients.[26, 27] In addition, the optimal 
cut-off value of the number of CTCs for the prognostic 
value in patients positive for CTCs was undetermined 
[28]. Furthermore, only approximately one-third of 
the patients had detectable CTCs, and the 
discrimination of survival differences among those 
patients who were negative for CTCs was impossible. 
Therefore, it is imperative that new techniques be 
developed for CTC enrichment and identification in 
order for a wide utilization of CTCs in mCRC. This 
study used a negative selection method of CD45 
depletion using magnetic beads followed by flow 
cytometry for CTC identification.[20, 21] CTCs were 
detected in all patients with mCRC, and the cut-off 
value of the median number of CTCs was analysed as 
an independent prognostic factor. Based on this 
simple and cheap method, we believed that CTCs 
may be widely available to use as a prognostic and 
predictive factor in mCRC patients who underwent 
palliative chemotherapy.  
To the best of our knowledge, this is the largest 
prospective study using a negative selection method 
for CTC isolation to evaluate the prognostic role of 
CTCs in patients with mCRC. Based on this simple 
method, the clinical variables of the prognostic model 
are accessible and available before palliative 
chemotherapy. Therefore, the current model is widely 
applicable and clinically relevant to identifying a 
small subset of patients with the poorest outcome. 
However, there are several inherent limitations of this 
study. First, this study included small numbers of 
patients, selected from a single medical centre; 
therefore, the statistically significant impact of clinical 
variables on survival outcome might be limited due to 
the small sample size. Second, the chemotherapy 
regimen was not consistent in all patients, so analysis 
of the baseline CTCs relevant to PFS and tumour 
response might be confounded by different treatment 
regimens. Finally, and most importantly, even though 
our prognostic model represented a good accuracy to 
predict 1-, 2-, and 3-year survival outcomes by the 
c-index, an external validation of the model is 
essential before it can be widely used. A prospective 
study is required to evaluate the prognostic and 
predictive values of this model in mCRC patients who 
underwent palliative chemotherapy.  
In conclusion, we identified the number of CTCs 
at the baseline of palliative chemotherapy as an 
independent prognostic factor for predicting survival 
outcome, in terms of overall survival, progression-free 
survival, and tumour response, in patients with 
mCRC. In addition, we developed a reliable 
CTC-based prognostic model for the prediction of 
survival outcome and treatment response in mCRC 
patients, after systemic chemotherapy. This model 
may be used to assist clinicians in identifying those 
mCRC patients with the poorest prognosis and 
treatment outcome. Further large-scale prospective 
trials to confirm the role of CTC prognosis score 
guiding anticancer strategies for each mCRC patient 
were eagerly warranted. 
Acknowledgements 
Funding for this study was received from the 
Chang Gung Memorial Hospital at Linkou 
(CMRPG3C1561 to Professor Wen-Chi Chou; 
CMRPG3E0512, CMRPG3G0591 and MOST 105-2314- 
B-182A- 030- to Dr. Chia-Hsun Hsieh; CMRPD 
2D0041-43 and CMRPD2E0011-1 to Professor 
Min-Hsien Wu). These funding sources were used in 
the designing and conducting of the study: they were 
used for collecting, managing, analysing, and 
interpreting the data, and preparing, reviewing, or 
approving the article. All authors declare no financial 
or other conflicts of interest. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence 
worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 
Accessed March 07, 2017. 
2. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, 
Al-Batran S-E, Heintges T, Lerchenmüller C, Kahl C, Seipelt G. FOLFIRI plus 
cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for 
patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, 
phase 3 trial. The lancet oncology. 2014; 15:1065-75. doi: 
10.1016/S1470-2045(14)70330-4. 
3. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony M, O'Neil BH, Shaw 
JE, Polite B, Hochster H, Atkins J. 501ocalgb/Swog 80405: phase III trial of 
irinotecan/5-Fu/leucovorin (folfiri) or oxaliplatin/5-Fu/leucovorin 
(mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with 
expanded Ras analyses untreated metastatic adenocarcinoma of the colon or 
rectum (mcrc). Annals of Oncology. 2014; 25:mdu438.13. doi: 
10.1093/annonc/mdu438.13. 
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben 
JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, 
Int. J. Biol. Sci. 2018, Vol. 14 
 
 
http://www.ijbs.com 
146 
disease progression, and survival in metastatic breast cancer. N Engl J Med. 
2004; 351: 781-91. doi: 10.1056/NEJMoa040766. 
5. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, 
Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, et al. Detection 
of circulating tumor cells in peripheral blood of patients with metastatic breast 
cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13: 
920-8. doi: 10.1158/1078-0432.CCR-06-1695. 
6. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle 
GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict 
survival benefit from treatment in metastatic castration-resistant prostate 
cancer. Clin Cancer Res. 2008; 14: 6302-9. doi: 10.1158/1078-0432.CCR-08-0872. 
7. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, 
Morse M, Mitchell E, Miller MC. Relationship of circulating tumor cells to 
tumor response, progression-free survival, and overall survival in patients 
with metastatic colorectal cancer. Journal of clinical oncology. 2008; 26: 
3213-21. doi: 10.1200/JCO.2007.15.8923. 
8. Lu YJ, Wang P, Peng J, Wang X, Zhu YW, Shen N. Meta-analysis Reveals the 
Prognostic Value of Circulating Tumour Cells Detected in the Peripheral 
Blood in Patients with Non-Metastatic Colorectal Cancer. Sci Rep. 2017; 7: 905. 
doi: 10.1038/s41598-017-01066-y. 
9. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific 
biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8: 
329-40. doi: 10.1038/nrc2375. 
10. Sergeant G, Penninckx F, Topal B. Quantitative RT-PCR detection of colorectal 
tumor cells in peripheral blood—a systematic review. Journal of Surgical 
Research. 2008; 150: 144-52. doi: 10.1016/j.jss.2008.02.012. 
11. Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, Thierry B. Detection 
and clinical significance of circulating tumor cells in colorectal cancer—20 
years of progress. Molecular Medicine. 2015; 21: S25. doi: 
10.2119/molmed.2015.00149. 
12. Chen D, Wen X, Song YS, Rhee YY, Lee TH, Cho NY, Han SW, Kim TY, Kang 
GH. Associations and prognostic implications of Eastern Cooperative 
Oncology Group performance status and tumoral LINE-1 methylation status 
in stage III colon cancer patients. Clin Epigenetics. 2016; 8: 36. doi: 
10.1186/s13148-016-0203-8. 
13. Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on 
Cancer) Cancer Staging Manual, 7th ed. Springer, New York 2010; p.133. 
14. Knox RD, Luey N, Sioson L, Kedziora A, Clarkson A, Watson N, Toon CW, 
Cussigh C, Pincott S, Pillinger S, Salama Y, Evans J, Percy J, et al. Medullary 
colorectal carcinoma revisited: a clinical and pathological study of 102 cases. 
Ann Surg Oncol. 2015; 22: 2988-96. doi: 10.1245/s10434-014-4355-5. 
15. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG. 
Significance of signet-ring cells in patients with colorectal cancer. Dis Colon 
Rectum. 2008; 51: 50-5. doi: 10.1007/s10350-007-9073-7. 
16. Newland RC, Dent OF, Lyttle MN, Chapuis PH, Bokey EL. Pathologic 
determinants of survival associated with colorectal cancer with lymph node 
metastases. A multivariate analysis of 579 patients. Cancer. 1994; 73: 2076-82. 
doi: 10.1002/1097-0142(19940415)73:8<2076:AID-CNCR2820730811>3.0.CO; 
2-6. 
17. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, 
Pingpank JF, Zeh H, 3rd, Bartels CJ, Lee KK, Bartlett DL. C-stage in colon 
cancer: implications of carcinoembryonic antigen biomarker in staging, 
prognosis, and management. J Natl Cancer Inst. 2011; 103: 689-97. doi: 
10.1093/jnci/djr078. 
18. Tarantino I, Warschkow R, Worni M, Cerny T, Ulrich A, Schmied BM, Güller 
U. Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 
Metastatic Colorectal Cancer Patients: A Population-based, Propensity 
Score–adjusted Trend Analysis. Annals of surgery. 2015; 262: 112-20. doi: 
10.1097/SLA.0000000000000860. 
19. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M. 32 INVITED New response evaluation 
criteria in solid tumors: revised RECIST guideline version 1.1. European 
Journal of Cancer Supplements. 2008; 6: 13. doi: 10.1016/j.ejca.2008.10.026. 
20. Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, 
Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, et al. Circulating Tumour Cells as 
an Independent Prognostic Factor in Patients with Advanced Oesophageal 
Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Sci Rep. 2016; 6: 
31423. doi: 10.1038/srep31423. 
21. Chiu T-K, Chou W-P, Huang S-B, Wang H-M, Lin Y-C, Hsieh C-H, Wu M-H. 
Application of optically-induced-dielectrophoresis in microfluidic system for 
purification of circulating tumour cells for gene expression analysis-Cancer 
cell line model. Scientific Reports. 2016; 6. doi: 10.1038/srep32851. 
22. Health registry annual Report 2013, Republic of China. Republic of China: 
Republic of China: Bureau of Health Promotion, Department of Health, 
Executive Yuan; 2015. Available at: http://www.hpa.gov.tw/BHPNet/ 
Web/Stat/Statistics.aspx. Accessed January 20, 2017. 
23. Chou WC, Yeh KY, Peng MT, Chen JS, Wang HM, Lin YC, Liu CT, Chang PH, 
Wang CH, Chen PT, Hung YS, Lu CH, Li SH. Development and Validation of 
a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors 
and Bone Marrow Metastases. Medicine (Baltimore). 2015; 94: e966. doi: 
10.1097/MD.0000000000000966. 
24. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance 
status scoring in lung cancer: a prospective, longitudinal study of 536 patients 
from a single institution. Eur J Cancer. 1996; 32A: 1135-41. doi: 
10.1016/0959-8049(95)00664-8. 
25. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific 
biological properties of disseminating tumour cells. Nature Reviews Cancer. 
2008; 8: 329-40. doi:  
26. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, 
Diener MK, Büchler MW, Koch M, Weitz J. Meta-analysis shows that detection 
of circulating tumor cells indicates poor prognosis in patients with colorectal 
cancer. Gastroenterology. 2010; 138: 1714-26. doi: 10.1053/j.gastro.2010.01.008. 
27. Koerkamp BG, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor 
cells and prognosis of patients with resectable colorectal liver metastases or 
widespread metastatic colorectal cancer: a meta-analysis. Annals of surgical 
oncology. 2013; 20: 2156-65. doi:  
28. Hsieh JCH, Wu TMH. The Selection Strategy for Circulating Tumor Cells 
(CTCs) Isolation and Enumeration: Technical Features, Methods, and Clinical 
Applications. Tumor Metastasis: InTech). 2016. 
. 
 
